Patents by Inventor Maxime Ferrand

Maxime Ferrand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunotherapy of Skeletal Myopathies Using ANTI-FAP CAR-T Cells
    Publication number: 20260053923
    Abstract: The invention relates to an immune cell engineered to express a chimeric antigen receptor (CAR) which specifically binds Fibroblast Activation Protein (FAP) for use in the treatment of skeletal muscle fibrosis in muscular dystrophies.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 26, 2026
    Applicants: Genethon, Institut National de la Santé et de la Recherche Médicale, Universite Evry Val D'Essonne
    Inventors: Anne Galy, Isabelle Richard, Céline Rocca, Sonia Albini, Maxime Ferrand
  • Use of Syncytin for Targeting Drug and Gene Delivery to Lung Tissue
    Publication number: 20210198636
    Abstract: The invention relates to a pharmaceutical composition for targeting drug delivery including gene delivery to lung tissue, comprising at least a therapeutic drug or gene associated to a syncytin protein, and its use in the prevention and/or treatment of lung diseases, in particular in gene therapy of said diseases using lentiviral vector particles or lentivirus-like particles pseudotyped with syncytin protein.
    Type: Application
    Filed: October 19, 2018
    Publication date: July 1, 2021
    Applicants: Genethon, Institut National de la Santé et de la Recherche Médicale, Université d'Evry val d'Essonne
    Inventors: Anne Galy, Youna Coquin, Maxime Ferrand
  • Use of a Syncytin for Targeting Drug and Gene Delivery to Regenerate Muscle Tissue
    Publication number: 20200261589
    Abstract: The invention relates to a pharmaceutical composition for targeting drug delivery including gene delivery to regenerating muscle tissue, comprising at least a therapeutic drug or gene, associated to a syncytin protein, and its use in the prevention and/or treatment of muscle injuries or diseases, in particular in gene therapy of said diseases using lentiviral vector particles or lentivirus-like particles pseudotyped with syncytin protein.
    Type: Application
    Filed: October 19, 2018
    Publication date: August 20, 2020
    Applicants: Genethon, Institut National de la Santé et de la Recherche Médicale, Université d'Evry val d'Essonne
    Inventors: Anne Galy, Maxime Ferrand